Alnylam Surprises Investors With Last-Minute HELIOS-B Revisions

 
• By Joseph Haas
Alnylam building
Alnylam's trial changes are intended to demonstrate monotherapy benefit with Amvuttra • Source: Shutterstock

More from Clinical Trials

More from R&D